These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 772175)

  • 21. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease: a comparison of mesulergine and bromocriptine.
    Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
    Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.
    Agid Y; Pollak P; Bonnet AM; Signoret JL; Lhermitte F
    Lancet; 1979 Mar; 1(8116):570-2. PubMed ID: 85162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dosages of bromocriptine added to levodopa in Parkinson's disease.
    Hoehn MM; Elton RL
    Neurology; 1985 Feb; 35(2):199-206. PubMed ID: 3969207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group.
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):77-82. PubMed ID: 2651567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J; Orman J; Jansson B
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
    Montastruc JL; Rascol O; Rascol A
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):773-5. PubMed ID: 2664089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ergot derivative in the treatment of Parkinson's disease.
    Calne DB; Shoulson I; Kartzinel R
    Postgrad Med J; 1976; 52suppl 1():81-5. PubMed ID: 183198
    [No Abstract]   [Full Text] [Related]  

  • 37. Lergotrile in Parkinson disease: further studies.
    Lieberman AN; Gopinathan G; Estey E; Kupersmith M; Goodgold A; Goldstein M
    Neurology; 1979 Feb; 29(2):267-72. PubMed ID: 34808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind trial of bromocriptine in Parkinson's disease.
    Mackenzie RA; Lance JW
    Med J Aust; 1978 Nov; 2(3 Suppl):27-8. PubMed ID: 370527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.